Radiopharmaceutical developer DraxImage has received a U.S. patent for a family of chelating compounds that could be used in the development of imaging and radiotherapeutic agents, according to the Mississauga, Ontario-based company. As described under U.S. patent 6,623,721, the invention describes the synthesis and application of high-affinity bifunctional chelators containing hydroxamic acid residues, DraxImage said.
These chelating agents have a molecular structure that also contains a reactive group, which permits attachment to biologically active substances such as peptides, proteins, or antibodies. As a result, a combination of a chelating agent with a biologically active compound could be subsequently radiolabeled with an appropriate radioisotope to form a new diagnostic or therapeutic agent, the company said.
By AuntMinnie.com staff writersOctober 2, 2003
Related Reading
DraxImage begins Infecton Phase II trials, July 31, 2003
Draxis divests Draxis Pharmaceutica, July 23, 2003
DraxImage, Bristol-Meyers Squibb extend partnership, July 2, 2003
Draxis shuffles management, June 3, 2003
DraxImage begins U.S. shipments of I-131 kit, April 3, 2003
Copyright © 2003 AuntMinnie.com
